Cancer Research Tools for Biological Relevance Bio Research BioResearch

BioResearch
Bio Research
Cancer Research Tools for
Biological Relevance
Os nos ad tat. Igna faccum eroses
iriusti onulla feuisisit adio con
veliquamcore magna alis nonulla
non er irilla am, quiscil dolobor
eu faccum quisisim quis nullaor
rem iril er summy nulpute tinos
ipisci te facilit nulla facilis molore.
Cancer Research and
Drug Discovery Tools
BioResearch
Cancer Research and Drug Discovery Tools
Avoid Research Roadblocks and Take a Direct Route to Results
“I need to understand the
origin of cancer and what
role cancer stem cells play
in cancer formation”
SOLUTION: Cancer stem cell
hypothesis and cancer formation
can be simulated optimally in
well-characterized primary cells.
Page 5
Primary Cells
and Media
“Efficient transfection of various
cancer cell lines or primary cells
with plasmids or siRNA requires a
lot of optimization effort.”
SOLUTION: Pick from more than
100 ready-to-use Nucleofection™
Protocols suited for high
efficiency with any nucleic acid
substrate. Page 8
Transfection
2
“I want to use primary cells for
high throughput drug screening,
but can't get large quantities of
homogenous primary cells.”
SOLUTION: Lonza offers
conditionally immortalized cells
from a wide range of human
tissues that offer primary-like
characteristics. Page 13
Drug Discovery Tools
“I can’t find reliable assay
tools to study drug effects
on protein expression, cell
proliferation, or cytotoxicity.”
SOLUTION: Choose from our
variety of assay tools, including
ready-to-use protein gels and
bioassay kits to measure cell
proliferation and cytotoxicity.
Page 14
Cell Analysis
3
BioResearch
Cancer Research and Drug Discovery Tools
Your Cancer Research Toolkit
relevant results, from high-quality primary cells,
through efficient transfection technology, to a
wide range of moleculary biology and cell culture
tools.
Streamline your workflow by choosing from
convenient, innovative research tools that have
been designed and tested to work together.
Lonza gives you what you need for biologically
Primary Cells
and Media
Clonetics™ Human Cells with
optimized growth media:
Blood & Lymph Cells
– Blood & lymphatic HMVECs
– Hematopoietic stem cells
– Mesenchymal stem cells
Bone Cells
–Osteoblasts
– Osteoclast precursors
–Fresh bone marrow and
progenitor cells
Breast Cells
– Mammary epithelial
Pancreatic Cells
– Pancreatic Islets
– Acinar tissue
Pulmonary Cells
–Bronchial epithelial &
smooth muscle
– Lung Fibroblasts and HMVECs
–Pulmonary artery endothelial
and smooth muscle
– Small airway epithelial cells
Reproductive and Renal Cells
–Prostate epithelial, smooth
muscle and stromal cells
–Uterine and Bladder endothelial
and smooth muscle cells
– Sertoli cells
Skin Cells
– Adult and neonatal HMVECs
–Fibroblasts
–Keratinocytes
–Melanocytes
–Pre-adipocytes and
Adipose-derived stem cells
Transfection
Drug Discovery Tools
Cell Analysis
Nucleofector™ Technology with optimized protocols for cancer-related
primary cells, including:
– Blood cells
– Epithelial cells
– Endothelial cells
– Neuronal cells
–Fibroblasts
– Adult or embryonic stem cells
Conditionally Immortalized
Human Cell Lines:
–Brain Microvascular
­Endothelial Cells
–Preadipocytes
– Skeletal Muscle Cells
– Dermal Fibroblasts
–Coronary Artery
Smooth Muscle Cells (CASMC)
–Blood (BEC) and Lymphatic
(LEC) Microvascular
Endothelial Cells
– Adult Dermal Keratinocytes
Cell Proliferation and Cytotoxicity
BioAssay Kits:
–ViaLight™ Kit for measuring
cell proliferation and
cytotoxicity
– ToxiLight™ Kit for non-destructive measurement
of cytotoxicity
Also optimized for more than
80 cancer-related cell lines,
including:
– Blood cancer (e.g. Jurkat)
– Breast cancer (e.g. MCF-7)
– Lung cancer (e.g. A549)
– Neurological cancer (e.g. C6)
– Prostate cancer (e.g. DU145)
Biowhittaker™ Liquid and
Powder Media for therapeutic
and research needs
Cell Function Assays:
–Bone mineralization and
resorption assays
–Adipogenesis and lipolysis
measurement assays
Mycoplasma Detection:
–MycoAlert™ Assay for
accurate, reliable and
universal mycoplasma
detection
DNA, RNA, and Protein Expression
Analysis:
–PAGEr™ EX Gels and ProSieve™
EX Reagents for protein analysis
and Western blotting
–FlashGel™ System for PCR
analysis and RNA integrity
analysis
4
Primary Cells and Media
We offer a wide variety of cells and optimized media kits for cancer research. Cells and media are tested together and guaranteed to perform.
“I need to understand the
origin of cancer and what
role cancer stem cells
play in cancer formation”
Primary cells are an essential component in research because they are
derived directly from human and animal tissue representing a living,
biologically relevant cell model. Primary cells have low modification/
mutation rate and require minimal pre-characterization prior to use. We
offer over 100+ primary cell types and optimized media kits for each.
Cells and media are tested together and guaranteed to perform.
SOLUTION: Cancer stem
cell hypothesis and
cancer formation can only
be simulated optimally
in well-characterized
primary cells.
Benefits of Primary Cells
–– Better alternatives to cell lines
Research shows, some cell lines may not be the cell type they
have historically been reported. In a study of over 500 leukemialymphoma cell lines, 15% of the cell lines were misidentified.1 In a
separate study, 18-36% of cell lines are found to be misidentified
or cross-contaminated.2 For this reason, government institutions
such as NIH mandates authentication of cultured cell lines as critical for grant applications to be considered of the highest quality.3
Primary cells could be used as both normal controls to extensively
characterize and validate your cell lines or they may solely act as
superior substitutes to cell lines.
–– Biologically relevant for biomarker discovery
Cell lines are prone to genotypic and phenotypic drift after continual
passaging and many journals and government funding programs
mandate authentication of cell lines prior to use in experiments. In
addition, between 3-10 cell lines are required from same origin to
build a comprehensive biomarker profile. This can drive up experimental costs significantly. Clonetics™ Primary Cells are extensively
validated and make biomarker discovery more comprehensive as
these retain cell surface markers and other genes relevant to actual
human tissue. Eliminate costly analyses of inconsistent data acquired from non-characterized cell lines or low-quality primary cells.
–– Ideal for discovery of anti-cancer drugs
Clonetics™ Primary Cells have successfully been published in drug
screening assays. They are ideal solution for testing new anticancer drugs as they are representative of actual human system.
The preclinical relevance of primary cells is becoming increasingly
significant in cancer therapeutics. Models developed in primary cell
culture can easily be replicated in actual animal studies. In addition,
drug resistance assays for chemotherapy have successfully been
refined by researchers using primary cells alone. Reduce the cost
and number of animals required for in vivo studies by refining your
experiments with primary cells first (figure1).
–– Understand how cancer forms
Research shows primary cells can successfully be transformed
into cancer cells through genetic mutations and expression of oncogenes. Replicate a cancer model in vitro using primary cells as
prototypes of in vivo environment.
–– Study Cancer Stem Cells
Cancer stem cells (CSCs) are stem-cell like components that originate from normal tissue stem cells. CSCs share several properties
with normal stem cells, such as their capacity for self-renewal and
their ability to differentiate. CSCs, currently, can only be studied in
primary cells or normal tissues as both contain sub-populations of
stem-cell markers. Research also shows primary cells can be reprogrammed into iPSCs and this is a vast area of study in cancer
research currently.
1) Drexler HG, Dirks WG, Matsuo Y and MacLeod RAF (2003) Leukemia 17, 416–426
2) Hughes P et al. (2007) Biotechniques 43:575-586
3)http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-017.html
5
BioResearch
Cancer Research and Drug Discovery Tools
% maximal response
Primary Cells and Cell Lines Show Variability in
Drug Dose Response
110
100
90
80
70
60
50
40
30
20
10
0
Some Pathways Can Only Be Studied
in Primary Cells
Isolated CTL
1
HEK 293
EC 50
2
primary HRE
CTL docked to target cell
3
[Camptothecin] nM
primary HRCE
HEK 293
HRE
HRCE
68.10
537.5
557.4
Figure 2. Some pathways can only be studied in primary cells as there is no cell line
to represent that pathway. Cytolytic T lymphocytes (CTLs) recognize foreign cells and
lyse them via the “immunological synapse”. At the immunological synapse CTLs secrete
cytolytic granules containing Perforin. hMUNC13-4 is involved in an activation step preceding vesicle membrane fusion in cytolytic granule secretion. Nucleofection™ of a plasmid
expressing hMUNC13-4/RFP fusion shows only partial co-localization of hMUNC13-4 (red,
H) and Perforin (green, I) in isolated CTLs (overlay J; blue: nuclei stained by DAPI). Upon
target cell contact (M) hMUNC13-4 polarizes and extensively co-localizes with Perforincontaining cytolytic granules at the immunological synapse (L).
Reprinted from: Feldmann J et al. (2003) Cell 115(4):461-73; with permission of Elsevier.
Figure 1. Primary cells and cell lines show variability in drug dose so data acquired
through cell lines cannot easily be replicated in an in vivo model. The three cell types
were dosed with Camptothecin for 48h and their cytotoxic response assessed using the ViaLight™ Assay.The ViaLight™ Assay measures the number of viable cells left
after drug challenge, measuring the ATP donated to the assay reaction by viable cells.
In this assay the data points are the mean of 40 replicates (8 replicates per plate;
5 plates). We have a marked difference in EC50 dose response almost
10 fold. The HEK 293 cell line required only 68nM Camptothecin to kill 50% of the cells.
In the case of the primary cells (HRE = human renal epithelial cells, HRCE = human renal
cortical epithelial cells) this dose was over 500nM a striking different response.
6
Clonetics™ Primary Cells
Poietics™ Adult Stem Cells and Media
Why use Clonetics™ Primary Cells?
−
Product quality – Superior to cell lines with minimum specs gua­
rantee. All Clonetics™ Cells are ISO-certified with extensive quality
control and batch-to-batch consistency
−Product availability – Readily available 100+ cell types (human
and animal) with donor variety and steady supply schedule
−
Reliability – Market leader in primary cells offering; 40+ years of
experience and 10× more publications than other providers
−
Cost-effective – No pre-characterization needed; No repeat
analyses; Refine experiments and reduce animal work
−
Easy to culture – Specialized support team to assist, optimized
protocols guaranteed to work
−
Convenience – Cryopreserved ampoule to store and use as needed
or proliferating in flasks/plates to save time
All of Lonza’s stem cells are guaranteed to be of high purity and possess
full differentiation capacity.
–– Studies have shown that mesenchymal stem cells can contribute to
cancer progression in a number of different cancers, primarily cancers affecting bone marrow, blood and lymph tissues. Lonza offers
cryopreserved human and rat Mesenchymal Stem Cells, as well as
optimized Mesenchymal Stem Cell Growth and Differentiation media.
–– Lonza has a variety of human hematopoietic stem cells from cord
blood and Bone marrow, along with specialized growth medium and
EasyDiff™ kits designed to differentiate CD34+ progenitors into Erythroid, Megakaryocyte and Myeloid Cell.
–– Lonza also offers Osteoclast Precursors, Preadipocytes and Adipose-Derived stem cells, along with specialized media for each, that
are perfect for studying various bone and lipoma tumors.
–– Lonza runs its own bone marrow donor program to collect normal
bone marrow aspirates from healthy donors for use in research.
This program provides a convenient, easy to access source of bone
marrow derived cells.
Case Study: Clonetics™ Human Prostate Epithelial Cells (PrECs) and Media in Cancer Stem
Cells Applications
Isotype
A
Counts
The Role of CD133 in Normal Human Prostate Stem Cells and Malignant
Cancer-Initiating Cells.
D. J. Vander Griend et.al. (2008) Cancer Res 68:9703-9711
ABCG2
CD133
200
160
120
80
40
101102103104
IgG-PE
B
104
101102103104
CD133-PE
–– Prostate cancer arises within the epithelial compartment and generally believed to begin within the stem-cells
–– In the adult human prostate, CD133/ABCG2 expression is indicative of
small population of putative stem cells that suppress differentiation
−Clonetics™ PrECs (Cat. No. CC-2555) were utilized alongside inhouse isolated PrEC’s to assess stem-cell like properties. Both
cell types were cultured in Clonetics™ PrEGM Growth Media
BulletKit (Cat. No. CC-3166). Both exhibit high expression of stem-cell
markers CD133/ABCG2 (figure 3)
103
104
103
104
104
105
105
101102103104
IgG-FITC
101102103104
101102103104
ABCG2-FITC
Figure 3. Expression of stem cell markers in PrEC cultures.
A: ABCG2-FITC and CD133-PE (AC141) expression in PrECs.
B: Dual-label flow cytometry showing that CD133+ cells are also ABCG2+
Reprinted from Cancer Res, 2008, 68:9703-9711, DJ Vander Griend et al, The Role of
CD133 in Normal Human Prostate Stem Cells and Malignant Cancer-Initiating Cells, with
permission from AACR.
7
BioResearch
Cancer Research and Drug Discovery Tools
Transfection of Cancer-related Primary Cells and Cell Lines
As the leading non-viral technology for transfection of difficult-to-transfect cell lines and primary cells, the Nucleofector™ Technology is an
important tool to help understand the up-regulation and down-regulation
of genes in the progression from normal to cancerous cells and identifying
potential drug targets.
“Efficient transfection of
various cancer cell lines
or primary cells with
plasmids or siRNA requires
a lot of optimization
effort.”
SOLUTION: Pick from more
than 100 ready-to-use
Nucleofection™ Protocols
suited for high efficiency
with any nucleic acid
substrate.
Benefit From
Applications
–– Study the role of genes in the progression from normal to cancerous cells
–– Identification of potential drug targets
–– Confirmation of findings based on a cell line in further cell lines or
even corresponding primary cells
–– Easy switch from overexpressing genes (via DNA, RNA or peptides)
to down-regulation (by siRNA or shRNA)
Blood Cancer
Breast cancer
Colon Cancer Liver Cancer
Neurological Cancer
Prostate Cancer
MG63
HeLa
Human PrEC
PC3
LnCAP
DU 145
U-87MG
Neuron, cortical, rat
SH-SY5Y
Neuro-2a [N2a]
GH3
IMR32
C6
NHBE
T84
Lung Cancer
Figure 4. Examples of cancer cell lines and primary cells successfully transfected by Nucleofection™.
Data shown represent average results from various data sets.
8
HMVEC-L
A549
Hep G2
Hepatocyte, human
HT29
HCT 116
HMEC
T-47D
MCF7
T cell, human (unstim.)
U-937
B cell, human
RAW 264.7
Raji
Ramos
K-562
Jurkat
100
90
80
70
60
50
40
30
20
10
0
HL-60
Average Transfection Efficiency (%)
–– Non-viral transfection of primary cells and difficult-to-transfect
cancer cell lines
–– Up to 90% transfection efficiency and high cell viability
–– High flexibility in cell types and substrates
–– Different platforms for low throughput and high throughput, for e.g.
siRNA screenings.
–– More than 100 ready-to-use Nucleofection™ Protocols for a huge
spectrum of primary cells and cancer cell lines, including blood,
breast and prostate cancer
–– More than 800 cancer-related publications reducing the effort to
optimize methodologies
–– Option of adherent Nucleofection™ adding more convenience and
circumventing trypsinization
Other
Choose the Nucleofection™ Platform That Suits Your Research Needs
Advanced Platform
96-well Add-on
High-throughput Platform
4D-Nucleofector™ System
96-well Shuttle™ System
384-well Nucleofector™ System Nucleofector™ 2b Device
Throughput (samples per run)
Low to medium (1 – 16)
Low to high (1 – 96)
High (384)
Low (1)
Reaction volume
20 µl + 100 µl
20 µl
20 µl
100 µl
Electrode material
Conductive polymer
Conductive polymer
Conductive polymer
Aluminum
Low cell numbers (20 µl)
5 × 10 to 1 × 10
5 × 10 to 1 × 10
5 × 10 to 1 × 10
–
High cell numbers (100 µl)
2 × 105 to 2 × 106
–
–
2 × 105 to 2 × 106
DNA Vector amount/sample
0.2 – 1 μg (20 µl)
1 – 5 μg (100 µl)
0.2 – 1 μg
0.2 – 1 μg
1 – 5 μg
siRNA amount/sample
(concentration 2 nM – 2 µM)
0.04 – 40 pmol (20 µl)
0.2 – 200 pmol (100 µl)
0.04 – 40 pmol
0.04 – 40 pmol
0.2 – 200 pmol
Adherent Nucleofection™
n
–
–
–
Compatibility with
96-well Shuttle™ System
n
–
–
–
Device
Basic Device
Unit
4
5
4
9
5
4
5
BioResearch
Cancer Research and Drug Discovery Tools
Overview of Successfully Transfected Cell Types
The table below shows a selection of cell types for which Nucleofection™
Protocols or data exist. Further cell types can be found in our cell database.
www.lonza.com/cell-database
Efficiency*
Viability*
Kit for 4D-Nucleofector™ and
96-well Shuttle™ Systems
Kit for Nucleofector™
II/2b Device
B cell, human
28–36%
84–92%
P3
Human B Cell
Dendritic cell, human
93–99%
12–75%
Contact Scientific Support
Human Dendritic Cell
Macrophage, human
42–59%
87–88%
P3
Human Macrophage
Monocyte, human
60-64%
62–81%
P3
Human Monocyte
T cell, human stim.
41–70%
83–90%
P3
Human T Cell
T cell, human unstim.
43–98%
51–92%
P3
Human T Cell
AML
20–70%
45–87%
Contact Scientific Support
Contact Scientific Support
B–CLL
30–60%
75–90%
Contact Scientific Support
Contact Scientific Support
CML
42%
80%
Contact Scientific Support
Contact Scientific Support
EL4 (Mouse T cell lymphoma)
65%
76%
SF
Cell Line L
HL-60 (Human acute myeloid leukemia)
90%
50–65%
SF
Cell Line V
Jurkat (Human T cell leukemia)
88%
90%
SE
Cell Line V
K-562 (Human CML-derived B cell line)
80–90%
88%
SF
Cell Line V
KG-1 (Human AML cell line)
70%
84%
SE/SF/SG
Cell Line R
Raji (Human Burkitt’s lymphoma)
84%
67–81%
SG
Cell Line V
Ramos (Human Burkitt’s lymphoma)
27–51%
70–77%
SG
Cell Line V
RAW 264.7 (Mouse macrophage leukemia)
60–65%
74–86%
SF
Cell Line V
THP-1 (Human acute monocytic leukemia)
47–68%
40–81%
SG
Cell Line V
U-937 (Human histiocytic lymphoma)
32–67%
62–89%
SG
Cell Line C
50–73%
66–98%
P3
HMEC
MCF7 (Human mammary gland adenocarcinoma)
72–78%
60%
SE
Cell Line V
MDA-MB-231 (Human breast adenocarcinoma)
73–89%
77%
SE
Cell Line V
MDA-MB-453 (Human breast adenocarcinoma)
54%
90%
SE/SF/SG
Cell Line C
MDA-MB-468 (Human breast adenocarcinoma)
60%
81%
SE/SF/SG
Cell Line V
SK-BR-3 (Human breast adenocarcinoma)
50%
94%
SE/SF/SG
Cell Line C
T-47D (Human mammary gland ductal carcinoma)
51-80%
94%
SE
Cell Line V
Caco-2 (Human colorectal adenocarcinoma)
59–82%
70–80%
SE
Cell Line T
HCT 116 (Human colorectal adenocarcinoma)
70–80%
65–76%
SE
Cell Line V
HT-29 (Human colorectal adenocarcinoma)
16–67%
57–94%
SF
Cell Line R
SW480 (Human colorectal adenocarcinoma)
60%
86%
SE/SF/SG
Cell Line V
Blood Cancer – Primary Cells
Blood Cancer – Cell Lines
Breast Cancer – Primary Cells
Epithelial, mammary (HMEC), human
Breast Cancer – Cell Lines
Colon Cancer – Cell Lines
10
Efficiency*
Viability*
Kit for 4D-Nucleofector™ and
96-well Shuttle™ Systems
Kit for Nucleofector™
II/2b Device
60–84%
P3
Human Chondrocyte
Connective Tissue/Bone Cancer – Primary Cells
Chondrocyte, human
65–75%
Connective Tissue/Bone Cancer – Cell Lines
MG-63 (Human osteosarcoma)
62–73%
60–90%
SE
Cell Line C
Saos-2 (Human osteosarcoma)
82%
79%
SE/SF/SG
Cell Line V
U-2 OS (Human osteosarcoma)
98%
88%
SE/SF/SG
Cell Line V
Epithelial, kidney, human
40%
65%
P3/P1
–
Epithelial, renal proximal tubule cells (RPTEC),
human
70%
90%
P3/P1
–
54%
59–69%
P3
–
Hep G2 (Human hepatocellular carcinoma)
41–95%
86–94%
SF
Cell Line V
Hep1B (Mouse hepatocarcinoma)
50–56%
SE/SF/SG
Cell Line R
HuH7 (Human hepatoma)
60–90%
95%
SE/SF/SG
Cell Line T
Endothelial, microvascular, lung (HMVEC–L), human 52–79%
48–52%
P5
HMVEC-L
Epithelial, bronchial (NHBE), human
50–65%
50–53%
P3
Basic Epithelial Cell
A549 (Human lung carcinoma)
72–81%
62–81%
SF
Cell Line T
Calu-3 (Human lung adenocarcinoma)
40–81%
54–90%
SE
Cell Line V
Calu-6 (Human lung carcinoma)
73%
50–87%
SE/SF/SG
Cell Line L
IMR-90 (Human lung embryonic fi broblasts)
51–65%
70%
SE
Cell Line R
NCI-H1299 [H1299] (Human lung cancer)
99%
75%
SE/SF/SG
Cell Line C
T84 (Human lung metastase from colorectal
carcinoma)
53–88%
50–83%
SF
Cell Line T
Kidney Cancer – Primary Cells
Liver Cancer – Primary Cells
Hepatocytes, human
Liver Cancer – Cell Lines
Lung Cancer – Primary Cells
Lung Cancer – Cell Lines
Neurological Cancer – Primary Cells
Astrocyte (NHA), human
83–85%
P3
Basic Glia Cell
Astrocyte, mouse
60%
60–70%
P3
Basic Glia Cell
Neuron, cerebellar granule, mouse
30–51%
80%
P3
Mouse Neuron
Neuron, cerebellar granule, rat
50–60%
50–70%
P3
Rat Neuron
Oligodendrocyte, rat
44%
60%
P3
Basic Glia Cell
Neuroblastoma
20–90%
P3
contact Scientific Support
11
Continued on next page
BioResearch
Cancer Research and Drug Discovery Tools
Efficiency*
Viability*
Kit for 4D-Nucleofector™ and
96-well Shuttle™ Systems
Kit for Nucleofector™
II/2b Device
C6 (Rat glioma)
92–94%
55–80%
SF
Cell Line V
GH3 (Rat pituitary tumor)
60–80%
60–84%
SE
Cell Line L
IMR-32 (Human neuroblastoma)
74–86%
45–63%
SF
Cell Line L
Neuro-2a [N2a] (Mouse neuroblastoma)
46–90%
81–97%
SF
Cell Line V
SH-SY5Y (Human neuroblastoma)
63–82%
40–80%
SF
Cell Line V
SKNAS (Human neuroblastoma)
41–57%
55–82%
SE/SF/SG
Cell Line T
SK-N-MC (Human neuroblastoma)
50–95%
30–60%
SF
Cell Line V
SK-N-SH (Human neuroblastoma)
85%
73%
SE/SF/SG
Cell Line V
CHO-K1 (Hamster ovary)
76–94%
53–97%
SF
Cell Line T
HeLa (Human cervical adenocarcinoma)
60–85%
80–89%
SE
Cell Line R
OVCAR3 (Human ovarian adenocarcinoma)
70–80%
70–95%
SE/SF/SG
Cell Line T
SK-OV-3 (Human ovarian adenocarcinoma)
89%
53%
SE/SF/SG
Cell Line V
43–67%
48–64%
P1
Basic Epithelial Cell
DU 145 (Human prostate carcinoma)
47–100%
70–92%
SE
Cell Line L
LNCaP (Human prostate carcinoma)
70–82%
45–80%
SF
Cell Line R
PC-3 (Human prostate adenocarcinoma)
83–88%
59–66%
SF
Cell Line V
Fibroblast, dermal (NHDF), human – adult
42–96%
74–100%
P2
Human Fibroblast
Fibroblast, dermal (NHDF), human – neo
90–98%
85–91%
P2
Human Fibroblast
Keratinocyte, adult (NHEK–Ad), human
51%
40–60%
Primary Cell Optimization
Human Keratinocyte
Keratinocyte, neonatal, pooled (NHEK–neo), human
39–78%
50–79%
P3
Human Keratinocyte
Melanocyte, neonatal (NHEM–neo), human
70%
55–60%
Primary Cell Optimization
Human Melanocyte
A2058 (Human skin melanoma)
81%
94%
SE/SF/SG
Cell Line C
A-375 (Human skin melanoma)
72%
97%
SE/SF/SG
Cell Line V
B16-F0 (Mouse skin melanoma)
84%
91%
SE/SF/SG
Cell Line R
CD34+ cell, bone marrow, human
82%
62–70%
P3
Human CD34+ Cell
Embryonic stem (ES) cell, human
20–78%
50–98%
P3
Human Stem Cell
Mesench. stem (MSC), human
55–88%
50–86%
P1
Human MSC
Neural stem cell (NSC), human
90%
P3 or P4
Basic Neuron
Neural stem cell (NSC), mouse
60–82%
P4
Mouse NSC
Neural stem cell (NSC), rat
42–46%
P3
Rat NSC
Neurological Cancer – Cell Lines
Ovarian/Cervical Cancer – Cell Lines
Prostate Cancer – Primary Cells
Epithelial, prostate (PrEC), human
Prostate Cancer – Cell Lines
Skin Cancer – Primary Cells
Skin Cancer – Cell Lines
Stem Cells
80%
* Approximate ranges extrapolated from larger result collections, including Lonza and customer data
12
Drug Discovery Tools
Clonetics™ Immortalized Cells (CCICs) –
Models for Screening Anti-Cancer Drugs
“I want to use primary
cells for high throughput
drug screening, but can't
get large quantities of
homogenous primary
cells.”
CCICs present a solution to drug screening with biologically relevant
cells. These cells maintain most of the valuable properties of a primary
cell but possess practically unlimited growth potential, thus representing an ideal model for cell based high throughput screening. Screen cells
for biomarkers and cancer drug targets efficiently with large volumes
of homogenous primary-like cell populations.
SOLUTION: Lonza offers
conditionally immortalized
cells from a wide range
of human tissues
that offer primary-like
characteristics.
(% over basal)
We offer following cell lines in our CCIC portfolio
–– Human Brain Microvascular Endothelial Cells
–– Human Preadipocytes
–– Human Skeletal Muscle Cells
–– Human Dermal Fibroblasts
–– Human Coronary Artery Smooth Muscle cells (CASMC)
–– Human Blood (BEC) and Lymphatic (LEC) Microvascular
Endothelial Cells
–– Human Adult Dermal Keratinocytes
400
A Passage 6
300
200
100
0
Classical & Specialty Media
(% over basal)
The Biowhittaker™ brand provides over 16 high quality media products
that fit a variety of cancer applications. Our highly referenced media
portfolio contains a variety of liquid and powder formulations that have
been supporting therapeutic and research needs for over 20 years. The
BioWhittaker™ brand includes classical media, reagent, or regulatory
friendly specialty media and is manufactured in accordance with cGMP
regulations.
400
Basal
-9
-8
-7
-6
[Insulin] M
B Passage 21
300
200
100
0
www.lonza.com/culturemedia
Basal
-9
-8
-7
-6
[Insulin] M
Figure 5. Conditionally immortalized skeletal muscle cells maintain the ability for
insulin dependent glycogen synthesis after extended passaging. XM15B1 myoblasts were
serum starved for 18 h in Ham’s F10 (Lonza) medium at 37°C and exposed to insulin for
2 h in serum free medium containing radiolabeled glucose. The synthesized glycogen
was quantified using a filter based radiometric assay. Cells show a dose dependent
increase in glycogen synthesis in response to insulin at early (A, passage 6) and late
(B, passage 21) passages.
13
BioResearch
Cancer Research and Drug Discovery Tools
Cell Analysis Tools for Cancer Research
Utilize Lonza’s research tools for every step of your workflow. Lonza provides everything you need for biologically relevant results – from culture
media, sample preparation, all the way through protein confirmation.
"I can’t find reliable assay
tools to study drug effects on, protein expression, cell proliferation, or
cytotoxicity.”
ViaLight™ Plus Kit
SOLUTION: Choose from
our variety of assay tools,
including ready-to-use
protein gels, and bioassay
kits to measure cell proliferation and cytotoxicity.
Measure cell proliferation and cytotoxicity by using stable bioluminescence to detect adenosine triphosphate (ATP):
–– Process and analyze a 96-well plate in less than 15 minutes
–– Detect as few as ten cells; allowing for lower seeding densities
and more assays
–– Easily perform scalable automation with our simple, no-shake
protocol
–– Add two reagents directly to your culture and read luminescence
–– Expand your dynamic range to five decades, in adherent or
suspension cultures
–– Run this test on a variety of luminometers or scintillation
counters
–– Avoid radioactive or toxic materials
AdipoLyze™ Lipolysis Detection Assay
The AdipoLyze™ Lipolysis Detection Assay is a fast, sensitive, fluorescent
in vitro assay used for detecting small quantities of glycerol in cells
undergoing lipolysis.
–– Quantify in vitro lipolysis of adipogenic cell lines and both
subcutaneous and visceral primary preadipocytes
–– Accurately detect very low levels of glycerol (down to 0.44 μM
or 0.04 μg/ml)
www.lonza.com/vialight
ToxiLight™ Kit
AdipoRed™ Assay Reagent
Check a compound’s cytotoxic effects non-destructively by measuring
adenylate kinase (AK) leakage from damaged cells:
–– Generate results from as few as 10 cells
–– Eliminate the need to lyse by monitoring cytotoxicity from
supernatant
–– Simply add a single reagent directly to cells, or to a supernatant
aliquot
–– Process and analyze a 96-well plate in less than 10 minutes
–– Freeze supernatants and return to your work later without losing
AK activity
The AdipoRed™ Assay Reagent is designed for assessing the effect of
compounds on the differentiation of preadipocytes or on lipid utilization
in mature adipocytes. This objective, high-throughput, homogeneous
fluorescence-based assay quantifies the accumulation of intracellular
triglycerides and provides significant advantages to drug discovery
efforts.
− More sensitive than other methods such as the Oil Red O assay
− Faster and easier than Northern and Western blots
www.lonza.com/toxilight
14
OsteoAssay™ Human Bone Plate
OsteoImage™ Mineralization Assay
The OsteoAssay™ Plate provides a thin layer of adherent real human bone
for the culture of primary human or non-human osteoclasts, osteoclast
precursors, or immortalized cell lines. Cells can be stained with standard cytochemical or immunofluorescent techniques. Assays of bone
resorption and osteoclast precursor differentiation can be performed
easily by sampling the cell culture supernatant.
The OsteoImage™ Mineralization Assay is a rapid, fluorescent in vitro
assay for assessing bone cell mineralization. The OsteoImage™ Assay
can quantitate in vitro mineralization by osteogenic stem cells, primary
osteoblasts, and osteoblast-like cell lines. It is based on specific binding
of the fluorescent OsteoImage™ Staining Reagent to the hydroxyapatite
portion of bone-like nodules deposited by cells. Unlike typical histochemical methods such as von Kossa and Alizarin red, neither of which
is hydroxyapatite specific, the OsteoImage™ Assay eliminates multiple
steps or tedious extraction steps.
––
––
––
––
––
Eliminates the need for dentine or animal bone slices
Simply seed cells onto the surface of the
OsteoAssay™ Plate
Use with a variety of cell types and cell-based assays
Contains real human bone for more biologically relevant results
–– Delivers qualitative, visual fluorescent microscopy or quantitative
plate reader results
–– Can be used with primary osteoblasts, osteoblast stem cells,
and osteoblast cell lines
–– Measures hydroxyapatite, similar to real bone
–– Completed in less than 90 minutes, without tedious extractions
–– Sensitive enough to detect time-dependent increases in
mineralization in differentiating cells
–– Scalable for use in 6-well up to 96-well plates
OsteoLyse™ Assay Kit
The OsteoLyse™ Assay Kit provides an easy to use protocol for quantitatively measuring in vitro osteoclast-mediated bone resorption in a
high-throughput format. Osteoclasts can be seeded onto the OsteoLyse™
plate using traditional cell culture protocols. The assay directly measures
the release of Europium-labeled collagen fragments into the osteoclast
cell culture supernatant via time resolved fluorescence, indicating their
resorption activity levels.
MycoAlert™ Mycoplasma Detection Assay
The MycoAlert™ Assay Kit is a selective biochemical test that exploits the
activity of specific mycoplasmal enzymes which are found in all 6 of
the main mycoplasma cell culture contaminants and the vast majority
of 180 species of mycoplasma.
–– No need to separately purchase bone matrices as human collagen
is bound to wells
–– Just seed cells onto the OsteoLyse™ Plate surface
–– Measure resorptive activity by simply sampling the cell culture
supernatant and counting via time-resolved fluorescence
–– Results in <20 minutes by a simple 2-step assay
–– Bioluminescence-based technology – no DNA extraction necessary
–– NEW! MycoAlert™ PLUS Kit for use with less sensitive plate
luminometers or multifunctional readers
www.lonza.com/mycoalert
15
BioResearch
Cancer Research and Drug Discovery Tools
Custom Research Solutions
Molecular Biology Products
Nucleic Acid Electrophoresis:
– FlashGel System
If you’re looking for customized research solutions or expert support
services, just ask your local Lonza representative. They can put you
in touch with experts that have decades of experience in cell isolation,
transfection, and testing services.
Protein Electrophoresis:
– PAGEr™ EX Gels
– ProSieve™ EX Reagents
Custom Cell and Screening Services
Lonza’s molecular biology products offer basic aspects of cancer research. Speed up your results from PCR analysis, RNA integrity analysis, to fragment isolation for cloning. Lonza’s FlashGel™ System can get
you there in minutes. For protein analysis and western blotting Lonza’s
PAGEr™ EX Gels and ProSieve™ EX Reagents help speed your research
from hours to minutes.
You can order virtually any human or animal cell through our vast tissue
network. Lonza’s isolation experts can provide you with:
–– A broad range of cells, packaged to your specifications
–– Customized treatments, such as cell pelleting, personalized media,
and specific treatment prior to cryopreservation
Scientific Support For advice or information on any Lonza product, just contact our
scientific support team. They offer:
–– More than 50 years of combined troubleshooting experience
–– Educational webinars
–– Real disease research application data
Y ou can find contact details for your regional support team on the
back of this brochure.
16
Ordering Information
Cell Type
Description
Cat# (cells)
Recommended
G rowth Media
Media Bulletkit
Cat #
HMVEC-dBIAd
Adult dermal blood microvascular endothelial
CC-2811
EGM-2MV
CC-3202
HMVEC-dBlNeo
Neonatal dermal blood microvascular endothelial
CC-2813
EGM-2MV
CC-3202
HMVEC-dLyAd
Adult dermal lymphatic microvascular endothelial
CC-2810
EGM-2MV
CC-3202
HMVEC-dLyNeo
Neonatal dermal lymphatic microvascular endothelial
CC-2812
EGM-2MV
CC-3202
HMVEC-L
Lung Microvascular Endothelial
CC-2527
EGM-2MV
CC-3202
HMVEC-Lly
Lung lymphatic microvascular endothelial
CC-2814
EGM-2MV
CC-3202
CD133+
Hematopoietic Stem Cells from cord blood CD133+ 100,000 cells
2C-102A
HPGM
PT-3926
CD133+
Hematopoietic Stem Cells from cord blood CD133+ 500,000 cells
2C-102
HPGM
PT-3926
CD34+
Hematopoietic Stem Cells from cord blood CD34+ 100,000 cells
2C-101B
HPGM
PT-3926
CD34+
Hematopoietic Stem Cells from cord blood CD34+ 500,000 cells
2C-101A
HPGM
PT-3926
CD34+
Hematopoietic Stem Cells from cord blood CD34+ 1 million cells
2C-101
HPGM
PT-3926
MSC
Human Mesenchymal Stem Cells
PT-2501
MSCGM
PT-3001
MSC
Rat Mesenchymal Stem Cells
PT-2505
Rat MSCGM
192853
NHOst
Osteoblasts
CC-2538
OGM
CC-3207
NHAC-kn
Articular chondrocytes, knee
CC-2550
CDM
CC-3225
HPdLF
Peridontal ligament fibroblasts
CC-7049
SCGM
CC-3205
R-OST
Rat calvariae osteoblasts
R-Ost-583
DMEM high glucose and
Rat MSCGM SQ kit
N/A
Osteoclalsts
Osteoclast Precursors
2T-110
OCP
PT-8001
CD133+
Bone Marrow CD133+ 100 000 cells
2M-102A
HPGM
PT-3926
CD133+
Bone Marrow CD133+ 500 000 cells
2M-102
HPGM
PT-3926
Bone marrow
Fresh Bone Marrow
Cells on Demand
N/A
N/A
Mammary epithelial
CC-2551
MEGM
CC-3150
Islets
Fresh Human Pancreatic Islets 100K IEQ
201981
Supplemented Islet Media Included with Product
Islets
Fresh Human Pancreatic Islets 20K IEQ
201983
Supplemented Islet Media Included with Product
Islets
Fresh Human Pancreatic Islets 10K IEQ
210984
Supplemented Islet Media Included with Product
Islets
Fresh Human Pancreatic Islets 5K IEQ
201985
Supplemented Islet Media Included with Product
Islets
Fresh Human Pancreatic Islets 2K IEQ
202998
Supplemented Islet
Media
Islets
Frozen Pancreatic Islets
Cells on Demand
N/A
N/A
Pancreas
Acinar Tissue
Cells on Demand
N/A
N/A
Blood and Lymph
Bone
Breast
HMEC
Pancreatic
Included with Product
Continued on next page
17
BioResearch
Cancer Research and Drug Discovery Tools
Ordering Information
Cell Type
Description
Cat# (cells)
Recommended
G rowth Media
Media Bulletkit
Cat #
SAEC
Small Airway epithelial
CC-2547
SAGM
CC-3118
NHBE with RA
Bronchial/Tracheal epithelial with retinoic acid
CC-2540
BEGM
CC-3170
NHBE without RA
Bronchial/Tracheal epithelial without retinoic acid
CC-2541
BEGM
CC-3170
NHLF
Lung fibroblasts
CC-2512
FGM-2
CC-3132
HMVEC-L
Lung Microvascular Endothelial
CC-2527
EGM-2MV
CC-3202
HPAEC
Pulmonary artery endothelial
CC-2530
EGM-2
CC-3162
PASMC
Pulmonary artery smooth muscle cells
CC-2581
SmGM-2
CC-3182
BSMC
Bronchial Smooth muscle
CC-2576
SmGM-2
CC-3182
HMVEC-Lly
Lung lymphatic microvascular endothelial
CC-2814
EGM-2MV
CC-3202
UtMVEC-Myo
Uterine microvascular endothelial
CC-2564
EGM-MV
CC-3125
UtSMC
Uterine smooth muscle
CC-2562
SmGM-2
CC-3182
UASMC
Umbilical artery smooth muscle
CC-2579
SmGM-2
CC-3182
PrEC
Prostate epithelial
CC-2555
PrEGM
CC-3166
PrSC
Prostate stromal
CC-2508
SCGM
CC-3205
PrSMC
Prostate smooth muscle
CC-2587
SmGM-2
CC-3182
HSeC
Sertoli Cells
MM-HSE-2305
SeGM
191053
Lung
Reproductive
BdSMC
Bladder Smooth Muscle
CC-2533
SmGM-2
CC-3182
HMVEC-Bd
Bladder microvascular endothelial
CC-7016
EGM-2MV
CC-3202
HMVEC-dAd
Adult dermal microvascular endothelial
CC-2543
EGM-2MV
CC-3202
HMVEC-dBIAd
Adult dermal blood microvascular endothelial
CC-2811
EGM-2MV
CC-3202
HMVEC-dBlNeo
Neonatal dermal blood microvascular endothelial
CC-2813
EGM-2MV
CC-3202
HMVEC-dLyAd
Adult dermal lymphatic microvascular endothelial
CC-2810
EGM-2MV
CC-3202
HMVEC-dNeo
Neonatal dermal microvascular endothelial
CC-2505
EGM-2MV
CC-3202
HMVEC-dLyNeo
Neonatal dermal lymphatic microvascular endothelial
CC-2812
EGM-2MV
CC-3202
NHDF-Ad
Adult dermal fibroblasts
CC-2511
FGM-2
CC-3132
NHDF-Neo
Neonatal dermal fibroblasts
CC-2509
FGM-2
CC-3132
NHEK-Ad
Epidermal keratinocytes, Adult
192627
KGM-Gold
192060
NHEK-Neo
Epidermal keratinocytes, Neonatal
192907
KGM-Gold
192060
NHEK-Neo Pooled
Epidermal keratinocytes, neonatal pooled
192906
KGM-Gold
192060
NHEM-Neo
Neonatal normal human epidermal melanocytes
CC-2504
MGM-4
CC-3249
NHEM-Ad
Adult normal human epidermal melanocytes
CC-2586
MGM-4 + ET-3 Supplement CC-3249 + CC-4510
Preadipocytes
Preadipocytes, subcutan 4 million cells
PT-5001
PGM-2
PT-8002
Preadipocytes
Preadipocytes, visceral 1 million cells
PT-5005
PGM-2
PT-8002
Preadipocytes
Preadipocytes, sub cutan 1 million cells
PT-5020
PGM-2
PT-8002
ADSC
Adipose-derived stem cells
PT-5006
ADSC
PT-4505
Dermal (Skin)
18
Cell Type
Description
Cat# (cells)
Recommended
G rowth Media
Media Bulletkit
Cat #
Skeletal Muscle Tissue
HSMM
Skeletal Muscle myoblasts
CC-2580
SkGM-2
CC-3245
SkMC
Skeletal muscle cells
CC-2561
SkGM
CC-3160
NHA
Astrocytes
CC-2565
AGM
CC-3186
R-Cx
Rat Brain cortex neurons
R-Cx-500
PNGM
CC-4461
R-Hi
Rat brain hippocampus neurons
R-Hi-501
PNGM
CC-4461
R-Cp
Rat brain striatum neurons
R-Cp-502
PNGM
CC-4461
R-Drg
Rat dorsal root ganglion neurons
R-Drg-505
PNGM
CC-4461
R-eDrg
Embryonic rat dorsal root ganglion neurons
R-eDrg-515
PNGM
CC-4461
R-Cb
Rat cerebellar neurons
R-Cb-503
PNGM-A
CC-4512
R-HTh
rat brain hypothalamic neurons
R-HTh-507
PNGM
CC-4461
R-CxAs
Rat brain cortex astrocytes
R-CxAs-520
AGM
CC-3186
R-HiAs
Rat brain hippocampus astrocytes
R-HiAs-521
AGM
CC-3186
R-CpAs
Rat brain striatum astrocytes
R-CpAs-522
AGM
CC-3186
R-AsM
Rat brain Cx-Hi-Cp mix astrocytes
R-AsM-530
AGM
CC-3186
M-Cx
Mouse CD1 brain cortex neurons
M-Cx-400
PNGM
CC-4461
M-Cp
Mouse CD1 brain striatum neurons
M-Cp-402
PNGM
CC-4461
M-Cx
Mouse C57 brain cortex neurons
M-Cx-300
PNGM
CC-4461
M-Cp
Mouse C57 brain striatum neurons
M-Cp-302
PNGM
CC-4461
M-AsM
Mouse CD1 brain mixed astrocytes
M-AsM-430
AGM
CC-3186
M-AsM
Mouse CD57 brain mixed astrocytes
M-AsM-330
AGM
CC-3186
M-Hi
Mouse brain hippocampus neurons
M-Hi-401
PNGM
CC-4461
Neural Cells
Continued on next page
19
BioResearch
Cancer Research and Drug Discovery Tools
Ordering Information
Description
Cat. No.
Nucleofector™ Devices
4D-Nucleofector™ Core Unit
AAF-1002B
–
4D-Nucleofector™ X Unit
AAF-1002X
Requires core unit to build complete system
4D-Nucleofector™ Y Unit
AAF-1002Y
Requires core unit to build complete system
4D-Nucleofector™ Guarantee, 2-year extension
AWE-1002
Has to be purchased at the time the device is purchased
4D-Nucleofector™ Service Contract
AWC-1001
Can be purchased at any time during the guarantee period
96-well Shutte™ add-on (including laptop)
AAM-1001S
Requires core and X unit to build complete system
96-well Shutte™ Guarantee, 2-year extension
AWM-1002
Has to be purchased at the time the device is purchased
96-well Shutte™ Service Contract
AWB-1001
Can be purchased at any time during the guarantee period
HT Nucleofector™ System
AAU-1001
–
HT Nucleofector™ Installation and Training
AWT-1001
HT Nucleofector™ Service Contract
AWU-1001
Nucleofector™ 2b Device
AAB-1001
–
Nucleofector™ 2b Guarantee, 2-year extension
AWD-2002
Has to be purchased at the time the device is purchased
Nucleofector™ 2b Service Contract
AWA-2001
Can be purchased at any time during the guarantee period
Can be purchased at any time during the guarantee period
100 μl Nucleocuvette™
20 μl Nucleocuvette™; 16-well
Dipping Electrode
12 rxn
24 rxn
32 rxn
24 rxn
P1 Primary Cell 4D-Nucleofector™ X Kit
V4XP-1012
V4XP-1024
V4XP-1032
–
P2 Primary Cell 4D-Nucleofector™ X Kit
V4XP-2012
V4XP-2024
V4XP-2032
–
P3 Primary Cell 4D-Nucleofector™ X Kit
V4XP-3012
V4XP-3024
V4XP-3032
–
P4 Primary Cell 4D-Nucleofector™ X Kit
V4XP-4012
V4XP-4024
V4XP-4032
–
P5 Primary Cell 4D-Nucleofector™ X Kit
V4XP-5012
V4XP-5024
V4XP-5032
–
Primary Cell Optimization 4D-Nucleofector™ X Kit
–
–
V4XP-9096 (96 rxn)
–
AD1 4D-Nucleofector™ Y Kit (adherent)
–
–
–
V4YP-1A24
AD2 4D-Nucleofector™ Y Kit (adherent)
–
–
–
V4YP-2A24
Optimization 4D-Nucleofector™ Y Kit (adherent)
–
–
–
V4YP-9A48
SE Cell line 4D-Nucleofector™ X Kit
V4XC-1012
V4XC-1024
V4XC-1032
–
SF Cell line 4D-Nucleofector™ X Kit
V4XC-2012
V4XC-2024
V4XC-2032
–
SG Cell line 4D-Nucleofector™ X Kit
V4XC-3012
V4XC-3024
V4XC-3032
–
Cell Line Optimization 4D-Nucleofector™ X Kit
–
–
V4XC-9096 (64 rxn)
–
4D-Nucleofector™ Kits
20 μl Nucleocuvette™; 96-well
96 rxn
960 rxn
P1 Primary Cell 96-well Nucleofector™ Kit
V4SP-1096
V4SP-1960
P2 Primary Cell 96-well Nucleofector™ Kit
V4SP-2096
V4SP-2960
P3 Primary Cell 96-well Nucleofector™ Kit
V4SP-3096
V4SP-3960
P4 Primary Cell 96-well Nucleofector™ Kit
V4SP-4096
V4SP-4960
P5 Primary Cell 96-well Nucleofector™ Kit
V4SP-5096
V4SP-5960
Primary Cell Optimization 96-well Nucleofector™ Kit
V4SP-9096 (160 rxn)
–
SE Cell line 96-well Nucleofector™ Kit
V4SC-1096
V4SC-1960
SF Cell line 96-well Nucleofector™ Kit
V4SC-2096
V4SC-2960
SG Cell line 96-well Nucleofector™ Kit
V4SC-3096
V4SC-3960
Cell Line Optimization 96-well Nucleofector™ Kit
V4SC-9096
–
96-well Shuttle™ Kits
20
20 μl Nucleocuvette™; 384-well
768 rxn
3840 rxn
P1 Primary Cell 384-well Nucleofector™ Kit
V5SP-1002
V5SP-1010
P2 Primary Cell 384-well Nucleofector™ Kit
V5SP-2002
V5SP-2010
P3 Primary Cell 384-well Nucleofector™ Kit
V5SP-3002
V5SP-3010
P4 Primary Cell 384-well Nucleofector™ Kit
V5SP-4002
V5SP-4010
P5 Primary Cell 384-well Nucleofector™ Kit
V5SP-5002
V5SP-5010
Primary Cell Optimization 384-well Nucleofector™ Kit
V5SP-9001 (384 rxn)
–
SE Cell line 384-well Nucleofector™ Kit
V5SC-1002
V5SC-1010
SF Cell line 384-well Nucleofector™ Kit
V5SC-2002
V5SC-2010
SG Cell line 384-well Nucleofector™ Kit
V5SC-3002
V5SC-3010
Cell Line Optimization 384-well Nucleofector™ Kit
V5SC-9001 (384 rxn)
–
384-well Nucleofector™ Kits
100 µl Aluminum Cuvette
10 rxn
25 rxn
4x25 rxn
Human B Cell Nucleofector™ Kit
VAPA-1001
VPA-1001
VVPA-1001
Human T Cell Nucleofector™ Kit
VAPA-1002
VPA-1002
VVPA-1002
Human CD34+ Cell Nucleofector™ Kit
VAPA-1003
VPA-1003
VVPA-1003
Human Dendritic Cell Nucleofector™ Kit
VAPA-1004
VPA-1004
VVPA-1004
Human NK Cell Nucleofector™ Kit
VAPA-1005
VPA-1005
VVPA-1005
Mouse T Cell Nucleofector™ Kit
–
VPA-1006
VVPA-1006
Human Monocyte Nucleofector™ Kit
–
VPA-1007
VVPA-1007
Human Macrophage Nucleofector™ Kit
VAPA-1008
VPA-1008
VVPA-1008
Mouse Macrophage Nucleofector™ Kit
VAPA-1009
VPA-1009
VVPA-1009
Mouse B Cell Nucleofector™ Kit
VAPA-1010
VPA-1010
VVPA-1010
Mouse Dendritic Cell Nucleofector™ Kit
VAPA-1011
VPA-1011
VVPA-1011
VAPF-1001
VPF-1001
VVPF-1001
VAPE-1002
VPE-1002
VVPE-1002
Nucleofector™ II/2b Kits
Primary Blood Cells
Primary Bone/Cartilage Cells
Human Chondrocyte Nucleofector™ Kit
Primary Cardiac Cells
Rat Cardiomyocytes - Neonatal Nucleofector™ Kit
Primary Dermal Cells
Human Keratinocyte Nucleofector™ Kit
VAPD-1002
VPD-1002
VVPD-1002
Normal Human Epidermal Melanocyte-Neo Nucleofector™ Kit
VAPD-1003
VPD-1003
VVPD-1003
Human Coronary Artery Endothelial Cell Nucleofector™ Kit
VAPB-1001
VPB-1001
VVPB-1001
Human Umbilical Vein Endothelial Cell Nucleofector™ Kit
VAPB-1002
VPB-1002
VVPB-1002
Human Microvascular Endothelial Cell Lung Nucleofector™ Kit
VAPB-1003
VPB-1003
VVPB-1003
Basic Nucleofector™ Kit for Mammalian Endothelial Cells
VAPI-1001
VPI-1001
VVPI-1001
Primary Endothelial Cells
Primary Epithelial Cells
Normal Human Bronchial Epithelial Cell Nucleofector™ Kit
VAPK-1001
VPK-1001
VVPK-1001
Basic Nucleofector™ Kit for Mammalian Epithelial Cells
VAPI-1005
VPI-1005
VVPI-1005
Continued on next page
21
BioResearch
Cancer Research and Drug Discovery Tools
Ordering Information
100 µl Aluminum Cuvette
10 rxn
25 rxn
4x25 rxn
Human Dermal Fibroblast Nucleofector™ Kit
VAPD-1001
VVPD-1001
VPD-1001
Mouse Embryonic Fibroblast Nucleofector™ Kit 1
VAPD-1004
VPD-1004
VVPD-1004
Mouse Embryonic Fibroblast Nucleofector™ Kit 2
VAPD-1005
VPD-1005
VVPD-1005
Mouse Embryonic Fibroblast Starter Nucleofector™ Kit
VPD-1006
–
–
Basic Nucleofector™ Kit for Mammalian Fibroblasts
VAPI-1002
VPI-1002
VVPI-1002
VAPL-1004
VPL-1004
VVPL-1004
Mouse Neuron Nucleofector™ Kit
VAPG-1001
VPG-1001
VVPG-1001
Chicken Neuron Nucleofector™ Kit
VAPG-1002
VPG-1002
VVPG-1002
Rat Neuron Nucleofector™ Kit
VAPG-1003
VPG-1003
VVPG-1003
Basic Nucleofector™ Kit for Mammalian Neurons
VAPI-1003
VPI-1003
VVPI-1003
Basic Nucleofector™ Kit for Mammalian Glial Cells
VAPI-1006
VPI-1006
VVPI-1006
Human Aortic Smooth Muscle Cell Nucleofector™ Kit
VAPC-1001
VPC-1001
VVPC-1001
Basic Nucleofector™ Kit for Smooth Muscle Cells
VAPI-1004
VPI-1004
VVPI-1004
Human CD34+ Cell Nucleofector™ Kit
VAPA-1003
VPA-1003
VVPA-1003
Human Mesenchymal Stem Cell Nucleofector™ Kit
VAPE-1001
VPE-1001
VVPE-1001
Human Stem Cell Nucleofector™ Kit 1
VAPH-5012
VPH-5012
VVPH-5012
Human Stem Cell Nucleofector™ Kit 2
VAPH-5022
VPH-5022
VVPH-5022
Human Stem Cell Starter Nucleofector™ Kit
VPH-5002 (18 rxn)
–
–
Mouse Embryonic Stem Cell Nucleofector™ Kit
VPH-1001
VAPH-1001
VVPH-1001
Mouse Neural Stem Cell Nucleofector™ Kit
VAPG-1004
VPG-1004
VVPG-1004
Rat Neural Stem Cell Nucleofector™ Kit
VAPG-1005
VPG-1005
VVPG-1005
Cell Line Nucleofector™ Kit R
VACA-1001
VCA-1001
VVCA-1001
Cell Line Nucleofector™ Kit T
VACA-1002
VCA-1002
VVCA-1002
Cell Line Nucleofector™ Kit V
VACA-1003
VCA-1003
VVCA-1003
Cell Line Nucleofector™ Kit C
VACA-1004
VCA-1004
VVCA-1004
Cell Line Nucleofector™ Kit L
VACA-1005
VCA-1005
VVCA-1005
Cell Line Optimization Nucleofector™ Kit
VCO-1001N (18 rxn)
–
–
cGMP Cell Line Nucleofector™ Kit L
–
VGA-1005
–
cGMP Cell Line Nucleofector™ Kit V
–
VGA-1003
–
Nucleofector™ II/2b Kits
Primary Fibroblasts
Primary Hepatocytes
Mouse/Rat Hepatocyte Nucleofector™ Kit
Primary Neural Cells
Primary Smooth Muscle Cells
Primary Stem Cells
Cell Line Kits
22
Cat. No.
Size
Suited for
VS1-00500
500 µl
Primary Cell Kits (4D-Nucleofector™ System): P1, P2, P3, and P4
Cell Line Kits (4D-Nucleofector™ System): SE, SF and SG
Primary Cell Kits (Nucleofector™ II/2b Device): To determine the kits
compatible with Nucleofector™ PLUS-1 Supplement please refer to the
table provided on our website: www.lonza.com/n-plus
Cell Line Kits (Nucleofector™ II/2b Device): R, T, V, and L
Nucleofector™ PLUS Supplements
Nucleofector™ PLUS Supplement 1
Cat. No.
Description
Size
MycoAlert™ PLUS Mycoplasma Detection Kit
10 tests
BioAssay Kits
LT07-701
LT07-703
30 tests
LT07-705
50 tests
LT07-710
100 tests
LT07-518
MycoAlert™ Assay Control Set
10 tests
LT07-221
ViaLight™ Plus Cell Proliferation and Cytotoxity BioAssay Kit
500 tests
LT07-121
1,000 tests
LT07-321
10,000 tests
LT17-221
500 tests (with 5 white TC plates)
LT17-517
ViaLight™ 100% Lysis Control Set (sold separately)
10 ml (200 tests)
LT07-217
ToxiLight™ Non-destructive Cytotoxity BioAssay Kit
500 tests
LT07-1117
1,000 tests
LT07-117
500 tests (with 5 white TC plates)
193339
AdipoLyze™ Lipolysis Detection Kit
1 x 96-wells
PT-7009
AdipoRed™ Adipogenesis Assay Reagent
5 × 4 ml
PA-1000
OsteoAssay Bone Plate
1 × 96-wells
PA-1500
OsteoLyse™ Bone Resorption Assay Kit
1 × 96-wells
PA-1503
OsteoImage™ Bone Mineralization Assay
5 × 96-wells
23
www.lonza.com /research
www.lonza.com/cancer
Contact Information
North America
Customer Service: 800 638 8174 (toll free)
order.us@lonza.com
Scientific Support: 800 521 0390 (toll free)
scientific.support@lonza.com
Europe
Customer Service: +32 87 321 611
order.europe@lonza.com
Scientific Support: +32 87 321 611
scientific.support.eu@lonza.com
International
Contact your local Lonza distributor
Customer Service: +1 301 898 7025
Fax: +1 301 845 8291
scientific.support@lonza.com
International Offices
Australia Austria
Belgium
Brazil
Denmark France Germany India Ireland Italy Japan Luxemburg Norway Poland Singapore Spain Sweden Switzerland The Netherlands United Kingdom + 61 3 9550 0883
0800 201 538 (toll free)
+ 32 87 321 611
+ 55 11 2069 8800
808 83 159 (toll free)
0800 91 19 81 (toll free)
0800 182 52 87 (toll free)
+91 40 4123 4000
1 800 654 253 (toll free)
800 789 888 (toll free)
+ 81 3 6264 0660
+32 87 321 611
800 16 557 (toll free)
+ 48 781 120 300
+ 65 6521 4379
900 963 298 (toll free)
020 790 220 (toll free)
0800 83 86 20 (toll free)
0800 022 4525 (toll free)
0808 234 97 88 (toll free)
Lonza Cologne GmbH
50829 Cologne, Germany
For research use only.
Not for use in diagnostic procedures.
The Nucleofector™ Technology is covered by patent and/
or patent pending rights owned by the Lonza Group Ltd
or its affiliates. Unless otherwise noted, all trademarks
herein are marks of the Lonza Group Ltd or its affiliates.
The information contained herein is believed to be correct and corresponds to the latest state of scientific and
technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the
results to be obtained from the use of such information
and no warranty is expressed or implied concerning the
use of these products. The buyer assumes all risks of
use and/or handling.
Any user must make his own determination and satisfy
himself that the products supplied by Lonza Group Ltd
or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i)
suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party’s
intellectual property rights.
© 2014 Lonza Cologne GmbH. All rights reserved.
CD-BR025 01/14
CD-BR025